NASDAQ : PHAR

Pharming Group N.V. — Company profile

Healthcare · Biotechnology · Netherlands

Last price 12.23 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 868.47M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kδ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3Kδ inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Details

NamePharming Group N.V.
SectorHealthcare
IndustryBiotechnology
Employees407
Founded1988
CeoFabrice Chouraqui
CountryNetherlands
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS71716E1055
Cusip71716E105
Cik1828316
Sic2834

Key executives

NameTitle
Leverne Marsh BPHARMCo-Chief Executive Officer and Chief Commercial Officer
Kenneth Lynard EMBA, M.Sc.Chief Financial Officer and Co-Chief Executive Officer
Mireille Sanders M.Sc.Chief Operations Officer
Michael K. LevitanVice President of Investor Relations and Corporate Communications
Ruud Van Outersterp L.L.M.Chief Legal and Compliance Officer and Company Secretary
Ines Bernal B.A.Chief People Officer
Dr. Anurag Relan M.D., MPHChief Medical Officer
Dr. Alexander Breidenbach M.B.A., Ph.D.Chief Business Officer
Dr. Magnus HanssonMedical Director
Dr. Bruno M. L. GiannettiConsultant

Contact

AddressDarwinweg 24, Leiden, 2333 CR, Netherlands
Phone31 71 524 7400
Websitehttps://www.pharming.com